Aytu biopharma announces continuing availability of adhd medication adzenys xr-odt(r) in response to reported generic adderall(r) xr supply disruptions

Adzenys xr-odt is fda-approved as bioequivalent to adderall xr reported supply disruptions of adderall xr generic equivalents have the potential to affect patient access to adhd medications englewood, co / accesswire / october 5, 2022 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced the continuing availability of adzenys xr-odt® (amphetamine) extended-release orally disintegrating tablets, cii in response to numerous reported supply disruptions affecting generic adderall® xr (mixed salts amphetamine) extended-release capsule, cii for the treatment of attention deficit hyperactivity disorder (adhd). adzenys xr-odt is bioequivalent to adderall xr and is the only fda-approved, extended-release, orally-disintegrating tablet formulation of amphetamine.
AYTU Ratings Summary
AYTU Quant Ranking